REFERENCES
- O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445(7123):106–110.
- Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445(7123):111–115.
- Yanhong Deng, Meijing Huang, Jianping Wang, Tongyu Lin, Jian Xiao, Yonghua Cai, Edward H Lin. 5-Fluorouracil up regulates the stemness markerCD133 expression in colon cancer cells. Chinese J Pathophysiol 2009;25(11):2187–2191.
- Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol 2007;27(21):7551–7559.
- Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8(5):387–398.
- Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009;457(7229):603–607.
- Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatouspolyposis. N Engl J Med 2000;342(26):1946–1952.
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. 2005;352:1071–1080.
- Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2(COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. 2006;98:736–747.
- Deng YH, Pu XX, Huang MJ, Xiao Jian, Zhou Jiaming, Tongyu Lin, Edward H Lin. 5-Fluorouracil upregulates the activity of Wnt signaling pathway inCD133-positive colon cancer stem-like cells. Chin J Cancer 2010;29(9):810–815.
- Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E, Seino S, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells 2011;29(9):1327–1337.
- Sgambato A, Puglisi MA, Errico F, Rafanelli F, Boninsegna A, Rettino A, Genovese G, Coco C, Gasbarrini A, Cittadini A. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. J Cell Physiol 2010;224(1):234–241.
- Haraguchi N, Ohkuma M, Sakashita H. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008;15(10):2927–2933.
- Lonnroth C, Andersson M, Nordgren S, Lundholm K. Downregulation of prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment. Int J Oncol 2012;41(1):15–23.
- Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 2008;68(4):1213–1220.
- Qi L, Sun B, Liu Z, Li H, Gao J, Leng X. Dickkopf-1 inhibits epithelial-mesenchymal transition of colon cancer cells and contributes to colon cancer suppression. Cancer Sci 2012;103(4):828–835.